Toxicogenomics: Applications to In Vivo Toxicology

Genomics in Drug Discovery and Development

Volumn , Issue , 2008, Pages 219-291

  Blomme, Eric ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Mechanistic toxicology and toxicogenomics; predictive toxicology and toxicogenomics; Toxicogenomics and in vivo toxicology applications

Indexed keywords

EID: 79956338933     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470409770.ch5     Document Type: Chapter

References (234)

1. Service RF. Surviving the blockbuster syndrome. Science 2004; 303: 1796-1799.
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-715.
3. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988; 25: 387-396.
4. Roberts SA. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 2001; 31: 557-589.
5. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007; 6: 636-649.
6. Ulrich RG, Friend SH. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat Rev 2002; 1: 84-88.
7. Yang Y, Blomme EA, Waring JF. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 2004; 150: 71-85.
8. Lovett RA. Toxicogenomics. Toxicologists brace for genomics revolution. Science 2000; 289: 536-537.
9. Larson JL. Toxicity evaluations: ICH guidelines and current practice. In: Rogge MC, Taft DR, editors. Preclinical Drug Development. Boca Raton, FL: Taylor & Francis Group, 2005;349-414.
10. Knight A. Systematic reviews of animal experiments demonstrate poor human clinical and toxicological utility. Altern Lab Anim 2007; 35: 641-659.
11. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004; 3: 226-236.
12. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32: 56-67.
13. Jacobson-Kram D, Contrera JF. Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens. Toxicol Sci 2007; 96: 16-20.
14. Kirkland D, Aardema M, Henderson L, Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat Res 2005; 584: 1-256.
15. Dorato MA, Engelhardt JA. The no-observed-adverse-effect-level in drug safety evaluations:use, issues, and definition(s). Regul Toxicol Pharmacol 2005; 42: 265-274.
16. Stevens JL. Future of toxicology-mechanisms of toxicity and drug safety: where do we go from here? Chem Res Toxicol 2006; 19: 1393-1401.
17. Spielmann H. Predicting the risk of developmental toxicity from in vitro assays. Toxicol Appl Pharmacol 2005; 207: 375-380.
18. Williams GM. Mechanisms of chemical carcinogenesis and application to human cancer risk assessment. Toxicology 2001; 166: 3-10.
19. Kramer JA, Curtiss SW, Kolaja KL, Alden CL, Blomme EA, Curtiss WC, Davila JC, Jackson CJ, Bunch RT. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem Res Toxicol 2004; 17: 463-470.
20. Monro A. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? Adverse Drug React Toxicol Rev 1993; 12: 5-34.
21. Robinson DE, MacDonald JS. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol 2001;29 Suppl:13-19.
22. Gintant GA, Su Z, Martin RL, Cox BF. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol Pathol 2006; 34: 81-90.
23. Searfoss GH, Ryan TP, Jolly RA. The role of transcriptome analysis in pre-clinical toxicology. Curr Mol Med 2005; 5: 53-64.
24. Suter L, Babiss LE, Wheeldon EB. Toxicogenomics in predictive toxicology in drug development. Chem Biol 2004; 11: 161-171.
25. Martin RL, Su Z, Limberis JT, Palmatier JD, Cowart MD, Cox BF, Gintant GA. In Vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc Pharmacol 2006; 48: 199-206.
26. Blomme EA, Ciurlionis R, Marsh KC, Waring JF, Yang Y. Evaluation of the effects of serial phlebotomy on the transcriptome of major tissues and on the response to toxicants in rats. Toxicol Lett 2008; 176: 138-148.
27. Foster WR, Chen SJ, He A, Truong A, Bhaskaran V, Nelson DM, Dambach DM, Lehman-McKeeman LD, Car BD. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates. Toxicol Pathol 2007; 35: 621-635.
28. Hardisty JF, Brix AE. Comparative hepatic toxicity: prechronic/chronic liver toxicity in rodents. Toxicol Pathol 2005; 33: 35-40.
29. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005; 28: 53-66.
30. Lewis JH. Drug-induced liver disease. Med Clin North Am 2000; 84: 1275-1311.
31. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38 Suppl 2:S44-S48.
32. Schuster D, Laggner C, Langer T. Why drugs fail-a study on side effects in new chemical entities. Curr Pharm Des 2005; 11: 3545-3559.
33. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-2220.
34. Boone L, Meyer D, Cusick P, Ennulat D, Bolliger AP, Everds N, Meador V, Elliott G, Honor D, Bounous D, Jordan H. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol 2005; 34: 182-188.
35. O'Brien PJ, Slaughter MR, Polley SR, Kramer K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim 2002; 36: 313-321.
36. Malarkey DE, Johnson K, Ryan L, Boorman G, Maronpot RR. New insights into functional aspects of liver morphology. Toxicol Pathol 2005; 33: 27-34.
37. Dai X, He YD, Dai H, Lum PY, Roberts CJ,Waring JF, Ulrich RG. Development of an approach for ab initio estimation of compound-induced liver injury based on global gene transcriptional profiles. Genome Inform 2006; 17: 77-88.
38. Ruepp S, Boess F, Suter L, de Vera MC, Steiner G, Steele T, Weiser T, Albertini S. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol Appl Pharmacol 2005; 207: 161-170.
39. Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, Bostian KA, Brady L, Browne LJ, Calvin JT, Day GJ, Breckenridge N, Dunlea S, Eynon BP, Furness LM, Ferng J, Fielden MR, Fujimoto SY, Gong L, Hu C, Idury R et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 2005; 119: 219-244.
40. Blomme EA, Yang Y, Brennan R, Jeffy B. Development and evaluation of gene expressionbased signatures predictive and diagnostic of bile duct hyperplasia in rats. Vet Pathol 2007; 44: 781.
41. Fielden MR, Eynon BP, Natsoulis G, Jarnagin K, Banas D, Kolaja KL. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol Pathol 2005; 33: 675-683.
42. Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, Buratto B, Roberts C, Schadt E, Ulrich RG. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 2001; 175: 28-42.
43. Werner M, Costa MJ, Mitchell LG, Nayar R. Nephrotoxicity of xenobiotics. Clin Chim Acta 1995; 237: 107-154.
44. Davis JW, Kramer JA. Genomic-based biomarkers of drug-induced nephrotoxicity. Expert Opin Drug Metab Toxicol 2006; 2: 95-101.
45. Loeb WF. The measurement of renal injury. Toxicol Pathol 1998; 26: 26-28.
46. Thukral SK, Nordone PJ, Hu R, Sullivan L, Galambos E, Fitzpatrick VD, Healy L, Bass MB, Cosenza ME, Afshari CA. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol Pathol 2005; 33: 343-355.
47. Omenn GS. Assessment of human cancer risk: challenges for alternative approaches. Toxicol Pathol 2001;29 Suppl:5-12.
48. Greim H, Gelbke HP, Reuter U, Thielmann HW, Edler L. Evaluation of historical control data in carcinogenicity studies. Hum Exp Toxicol 2003; 22: 541-549.
49. Guengerich FP. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 1988; 48: 2946-2954.
50. Michel C, Roberts RA, Desdouets C, Isaacs KR, Boitier E. Characterization of an acute molecular marker of nongenotoxic rodent hepatocarcinogenesis by gene expression profiling in a long term clofibric acid study. Chem Res Toxicol 2005; 18: 611-618.
51. Shibanuma M, Kuroki T, Nose K. Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor beta 1 and other growth factors. J Biol Chem 1992; 267: 10219-10224.
52. Kester HA, Blanchetot C, den Hertog J, van der Saag PT, Van der BB. Transforming growth factor-beta-stimulated clone-22 is a member of a family of leucine zipper proteins that can homo-and heterodimerize and has transcriptional repressor activity. J Biol Chem 1999; 274: 27439-27447.
53. Iida M, Anna CH, Gaskin ND, Walker NJ, Devereux TR. The putative tumor suppressor Tsc-22 is downregulated early in chemically induced hepatocarcinogenesis and may be a suppressor of Gadd45b. Toxicol Sci 2007; 99: 43-50.
54. Kawamata H, Nakashiro K, Uchida D, Hino S, Omotehara F, Yoshida H, Sato M. Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. Br J Cancer 1998; 77: 71-78.
55. Nakashiro K, Kawamata H, Hino S, Uchida D, Miwa Y, Hamano H, Omotehara F, Yoshida H, Sato M. Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res 1998; 58: 549-555.
56. Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis 2003; 24: 757-770.
57. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci 2004; 77: 19-34.
58. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res 2005; 575: 61-84.
59. Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat Res 2008; 637: 23-39.
60. Fielden MR, Brennan R, Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 2007; 99: 90-100.
61. Nie AY, McMillian M, Parker JB, Leone A, Bryant S, Yieh L, Bittner A, Nelson J, Carmen A, Wan J, Lord PG. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 2006; 45: 914-933.
62. Peters EH, Rojas-Caro S, Brigell MG, Zahorchak RJ, des Etages SA, Ruppel PL, Knight CR, Austermiller B, Graham MC, Wowk S, Banks S, Madabusi LV, Turk P, Wilder D, Kempfer C, Osborn TW, Willey JC. Quality-controlled measurement methods for quantification of variations in transcript abundance in whole blood samples from healthy volunteers. Clin Chem 2007; 53: 1030-1037.
63. Willey JC, Knight CR, Crawford EL, Olson DE, Hammersly J, Yoon Y, Sharief I. Use of standardized reverse transcription-polymerase chain reaction and the standardized expression measurement center in multi-institutional trials to develop meaningful lung cancer classification based on molecular genetic criteria. Chest 2004;125:155S-156S.
64. Willey JC, Crawford EL, Knight CR, Warner KA, Motten CA, Herness EA, Zahorchak RJ, Graves TG. Standardized RT-PCR and the standardized expression measurement center. Methods Mol Biol 2004; 258: 13-41.
65. Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC, Krawetz SA, Dix DJ. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol 2004; 194: 189-199.
66. Burczynski ME, Dorner AJ. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 2006; 7: 187-202.
67. Rockett JC, Kavlock RJ, Lambright CR, Parks LG, Schmid JE, Wilson VS, Wood C, Dix DJ. DNA arrays to monitor gene expression in rat blood and uterus following 17beta-estradiol exposure: biomonitoring environmental effects using surrogate tissues. Toxicol Sci 2002; 69: 49-59.
68. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
69. Aune TM, Maas K, Moore JH, Olsen NJ. Gene expression profiles in human autoimmune disease. Curr Pharm Des 2003; 9: 1905-1917.
70. Olsen NJ, Moore JH, Aune TM. Gene expression signatures for autoimmune disease in peripheral blood mononuclear cells. Arthritis Res Ther 2004; 6: 120-128.
71. Tang Y, Gilbert DL, Glauser TA, Hershey AD, Sharp FR. Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch Neurol 2005; 62: 210-215.
72. Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, Maganti V, Reddy PS, Strahs A, Immermann F, Spinelli W, Schwertschlag U, Slager AM, Cotreau MM, Dorner AJ. Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J Mol Diagn 2006; 8: 51-61.
73. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans Sr. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 2007; 104: 955-960.
74. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 2005; 102: 11023-11028.
75. Dressman HK, Muramoto GG, Chao NJ, Meadows S, Marshall D, Ginsburg GS, Nevins JR, Chute JP. Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med 2007;4:e106.
76. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, Brown PO. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003; 100: 1896-1901.
77. Kim SJ, Dix DJ, Thompson KE, Murrell RN, Schmid JE, Gallagher JE, Rockett JC. Effects of storage, RNA extraction, genechip type, and donor sex on gene expression profiling of human whole blood. Clin Chem 2007; 53: 1038-1045.
78. Larrey D, Tinel M, Pessayre D. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem Pharmacol 1983; 32: 1487-1493.
79. Amacher DE, Schomaker SJ, Boldt SE, Mirsky M. The relationship among microsomal enzyme induction, liver weight, and histological change in cynomolgus monkey toxicology studies. Food Chem Toxicol 2006; 44: 528-537.
80. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 2003; 33: 655-780.
81. Waring JF, Gum R, Morfitt D, Jolly RA, Ciurlionis R, Heindel M, Gallenberg L, Buratto B, Ulrich RG. Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology 2002;181-182:537-550.
82. Wolfgang GH, Robertson DG, Welty DF, Metz AL. Hepatic and adrenal toxicity of a novel lipid regulator in beagle dogs. Fundam Appl Toxicol 1995; 26: 272-281.
83. Hamadeh HK, Bushel PR, Jayadev S, Martin K, DiSorbo O, Sieber S, Bennett L, Tennant R, Stoll R, Barrett JC, Blanchard K, Paules RS, Afshari CA. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 2002; 67: 219-231.
84. Kemper B. Regulation of cytochrome P450 gene transcription by phenobarbital. Prog Nucleic Acid Res Mol Biol 1998; 61: 23-64.
85. Denison MS, Nagy Sr. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003; 43: 309-334.
86. Guerreiro N, Staedtler F, Grenet O, Kehren J, Chibout SD. Toxicogenomics in drug development. Toxicol Pathol 2003; 31: 471-479.
87. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003; 1619: 263-268.
88. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004; 279: 23847-23850.
89. Whitlock JP, Jr. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999; 39: 103-125.
90. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR. Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 2007; 71: 1475-1486.
91. Ohno M. Genetic and pharmacological basis for therapeutic inhibition of beta-and gamma-secretases in mouse models of Alzheimer's memory deficits. Rev Neurosci 2006; 17: 429-454.
92. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-685.
93. Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Chem 2007; 282: 24504-24513.
94. Beher D, Graham SL. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. Expert Opin Investig Drugs 2005; 14: 1385-1409.
95. Tomita T, Iwatsubo T. gamma-secretase as a therapeutic target for treatment of Alzheimer's disease. Curr Pharm Des 2006; 12: 661-670.
96. Evin G, Sernee MF, Masters CL. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 2006; 20: 351-372.
97. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-358.
98. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, Ryan TP. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003; 278: 46107-46116.
99. Nair S, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Liew C, Chan JY, Kong AN. Toxicogenomics of endoplasmic reticulum stress inducer tunicamycin in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Toxicol Lett 2007; 168: 21-39.
100. Shen G, Xu C, Hu R, Jain MR, Nair S, Lin W, Yang CS, Chan JY, Kong AN. Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm Res 2005; 22: 1805-1820.
101. Shen G, Xu C, Hu R, Jain MR, Gopalkrishnan A, Nair S, Huang MT, Chan JY, Kong AN. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol Cancer Ther 2006; 5: 39-51.
102. Zhang JN, Liu XG, Zhu M, Chiu FC, Li RC. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 1998; 10: 354-359.
103. Graham RA, Tyler LO, Krol WL, Silver IS, Webster LO, Clark P, Chen L, Banks T, LeCluyse EL. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes. J Biochem Mol Toxicol 2006; 20: 69-78.
104. Guth BD. Preclinical cardiovascular risk assessment in modern drug development. Toxicol Sci 2007; 97: 4-20.
105. Wallace KB, Hausner E, Herman E, Holt GD, MacGregor JT, Metz AL, Murphy E, Rosenblum IY, Sistare FD, York MJ. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004; 32: 106-121.
106. York M, Scudamore C, Brady S, Chen C, Wilson S, Curtis M, Evans G, Griffiths W, Whayman M, Williams T, Turton J. Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover Wistar rat. Toxicol Pathol 2007; 35: 606-617.
107. Anderson TD, Van Alstine WG, Ficken MD, Miskimins DW, Carson TL, Osweiler GD. Acute monensin toxicosis in sheep: light and electron microscopic changes. Am J Vet Res 1984; 45: 1142-1147.
108. Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol 2007; 23: 27-37.
109. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905.
110. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol 2004; 378: 340-361.
111. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
112. Kalivendi SV, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J, Kalyanaraman B. Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription:role of mitochondrial reactive oxygen species and calcium. Biochem J 2005; 389: 527-539.
113. Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol 2007; 7: 135-139.
114. Chaiswing L, Cole MP, St Clair DK, Ittarat W, Szweda LI, Oberley TD. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol 2004; 32: 536-547.
115. Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D, Leeuwenburgh C. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 2004; 577: 483-490.
116. Gu YG, Weitzberg M, Clark RF, Xu X, Li Q, Lubbers NL, Yang Y, Beno DW, Widomski DL, Zhang T, Hansen TM, Keyes RF, Waring JF, Carroll SL, Wang X, Wang R, Healan-Greenberg CH, Blomme EA, Beutel BA, Sham HL et al. N-{macrosleftcurlybrace3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-coA carboxylase inhibitors-improvement of cardiovascular and neurological liabilities via structural modifications. J Med Chem 2007; 50: 1078-1082.
117. Tong L, Harwood HJ, Jr. Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem 2006; 99: 1476-1488.
118. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004; 3: 340-351.
119. Abu-Elheiga L, Almarza-Ortega DB, Baldini A, Wakil SJ. Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms. J Biol Chem 1997; 272: 10669-10677.
120. Mao J, Chirala SS, Wakil SJ. Human acetyl-CoA carboxylase 1 gene: presence of three promoters and heterogeneity at the 5'-untranslated mRNA region. Proc Natl Acad Sci USA 2003; 100: 7515-7520.
121. Abu-Elheiga L, Matzuk MM, Kordari P, Oh W, Shaikenov T, Gu Z, Wakil SJ. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci USA 2005; 102: 12011-12016.
122. Oh W, Abu-Elheiga L, Kordari P, Gu Z, Shaikenov T, Chirala SS, Wakil SJ. Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice. Proc Natl Acad Sci USA 2005; 102: 1384-1389.
123. Boekelheide K. Mechanisms of toxic damage to spermatogenesis. J Natl Cancer Inst Monogr 2005;6-8.
124. Creasy DM. Evaluation of testicular toxicity in safety evaluation studies: the appropriate use of spermatogenic staging. Toxicol Pathol 1997; 25: 119-131.
125. Comhaire FH, Mahmoud AM, Schoonjans F. Sperm quality, birth rates and the environment in Flanders (Belgium). Reprod Toxicol 2007; 23: 133-137.
126. Richburg JH, Johnson KJ, Schoenfeld HA, Meistrich ML, Dix DJ. Defining the cellular and molecular mechanisms of toxicant action in the testis. Toxicol Lett 2002; 135: 167-183.
127. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001; 478: 1-21.
128. Petersen PM, Hansen SW, Giwercman A, Rorth M, Skakkebaek NE. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994; 5: 355-358.
129. Prahalathan C, Selvakumar E, Varalakshmi P. Lipoic acid ameliorates adriamycin-induced testicular mitochondriopathy. Reprod Toxicol 2005; 20: 111-116.
130. El Demerdash FM, Yousef MI, Kedwany FS, Baghdadi HH. Cadmium-induced changes in lipid peroxidation, blood hematology, biochemical parameters and semen quality of male rats:protective role of vitamin E and beta-carotene. Food Chem Toxicol 2004; 42: 1563-1571.
131. Morris ID, Phillips DM, Bardin CW. Ethylene dimethanesulfonate destroys Leydig cells in the rat testis. Endocrinology 1986; 118: 709-719.
132. Delic JI, Hendry JH, Morris ID, Shalet SM. Serum androgen binding protein and follicle stimulating hormone as indices of Sertoli cell function in the irradiated testis. Br J Cancer Suppl 1986; 7: 105-107.
133. Stewart J, Turner KJ. Inhibin B as a potential biomarker of testicular toxicity. Cancer Biomark 2005; 1: 75-91.
134. Anawalt BD, Bebb RA, Matsumoto AM, Groome NP, Illingworth PJ, McNeilly AS, Bremner WJ. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 1996; 81: 3341-3345.
135. Illingworth PJ, Groome NP, Byrd W, Rainey WE, McNeilly AS, Mather JP, Bremner WJ. Inhibin-B: a likely candidate for the physiologically important form of inhibin in men. J Clin Endocrinol Metab 1996; 81: 1321-1325.
136. Foresta C, Bettella A, Garolla A, Ambrosini G, Ferlin A. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005; 84: 654-661.
137. Majumdar SS, Winters SJ, Plant TM. Procedures for the isolation and culture of Sertoli cells from the testes of infant, juvenile, and adult rhesus monkeys (Macaca mulatta). Biol Reprod 1998; 58: 633-640.
138. Kukucka MA, Misra HP. Isolation and culture of highly enriched populations of Leydig cells from guinea-pig (Cavia porcellus) testes. Andrologia 1994; 26: 217-224.
139. Murugesan P, Balaganesh M, Balasubramanian K, Arunakaran J. Effects of polychlorinated biphenyl (Aroclor 1254) on steroidogenesis and antioxidant system in cultured adult rat Leydig cells. J Endocrinol 2007; 192: 325-338.
140. Adachi T, Ono Y, Koh KB, Takashima K, Tainaka H, Matsuno Y, Nakagawa S, Todaka E, Sakurai K, Fukata H, Iguchi T, Komiyama M, Mori C. Long-term alteration of gene expression without morphological change in testis after neonatal exposure to genistein in mice: toxicogenomic analysis using cDNA microarray. Food Chem Toxicol 2004; 42: 445-452.
141. Adachi T, Koh KB, Tainaka H, Matsuno Y, Ono Y, Sakurai K, Fukata H, Iguchi T, Komiyama M, Mori C. Toxicogenomic difference between diethylstilbestrol and 17beta-estradiol in mouse testicular gene expression by neonatal exposure. Mol Reprod Dev 2004; 67: 19-25.
142. Moustafa GG, Ibrahim ZS, Hashimoto Y, Alkelch AM, Sakamoto KQ, Ishizuka M, Fujita S. Testicular toxicity of profenofos in matured male rats. Arch Toxicol 2007; 81: 875-81.
143. Tully DB, Bao W, Goetz AK, Blystone CR, Ren H, Schmid JE, Strader LF, Wood CR, Best DS, Narotsky MG, Wolf DC, Rockett JC, Dix DJ. Gene expression profiling in liver and testis of rats to characterize the toxicity of triazole fungicides. Toxicol Appl Pharmacol 2006; 215: 260-273.
144. Shultz VD, Phillips S, Sar M, Foster PM, Gaido KW. Altered gene profiles in fetal rat testes after in utero exposure to di(n-butyl) phthalate. Toxicol Sci 2001; 64: 233-242.
145. Rockett JC, Christopher LJ, Brian GJ, Krawetz SA, Hughes MR, Hee KK, Oudes AJ, Dix DJ. Development of a 950-gene DNA array for examining gene expression patterns in mouse testis. Genome Biol 2001;2:14.1-14.9.
146. Ryu JY, Lee BM, Kacew S, Kim HS. Identification of differentially expressed genes in the testis of Sprague-Dawley rats treated with di(n-butyl) phthalate. Toxicology 2007; 234: 103-112.
147. Latini G, Del Vecchio A, Massaro M, Verrotti A, De Felice C. Phthalate exposure and male infertility. Toxicology 2006; 226: 90-98.
148. Mylchreest E, Cattley RC, Foster PM. Male reproductive tract malformations in rats following gestational and lactational exposure to di(n-butyl) phthalate: an antiandrogenic mechanism? Toxicol Sci 1998; 43: 47-60.
149. Saillenfait AM, Payan JP, Fabry JP, Beydon D, Langonne I, Gallissot F, Sabate JP. Assessment of the developmental toxicity, metabolism, and placental transfer of di-n-butyl phthalate administered to pregnant rats. Toxicol Sci 1998; 45: 212-224.
150. Lehmann KP, Phillips S, Sar M, Foster PM, Gaido KW. Dose-dependent alterations in gene expression and testosterone synthesis in the fetal testes of male rats exposed to di(n-butyl) phthalate. Toxicol Sci 2004; 81: 60-68.
151. Fukushima T, Yamamoto T, Kikkawa R, Hamada Y, Komiyama M, Mori C, Horii I. Effects of male reproductive toxicants on gene expression in rat testes. J Toxicol Sci 2005; 30: 195-206.
152. Linder RE, Klinefelter GR, Strader LF, Suarez JD, Roberts NL, Dyer CJ. Spermatotoxicity of dibromoacetic acid in rats after 14 daily exposures. Reprod Toxicol 1994; 8: 251-259.
153. Linder RE, Klinefelter GR, Strader LF, Veeramachaneni DN, Roberts NL, Suarez JD. Histopathologic changes in the testes of rats exposed to dibromoacetic acid. Reprod Toxicol 1997; 11: 47-56.
154. Linder RE, Klinefelter GR, Strader LF, Suarez JD, Dyer CJ. Acute spermatogenic effects of bromoacetic acids. Fundam Appl Toxicol 1994; 22: 422-430.
155. Blomme EA, Ciurlionis R, Milicic I, Carr T, Whitney K, Miller J et al. Role of cytochrome P450C17α in dibromoacetic acid-induced testicular toxicity in rats (Abstract). Proceedings of the 45th Annual Meeting of the Society of Toxicology, 1546, 2006.
156. Dalla VL, Vianello S, Belvedere P, Colombo L. Rat cytochrome P450c17 gene transcription is initiated at different start sites in extraglandular and glandular tissues. J Steroid Biochem Mol Biol 2002; 82: 377-384.
157. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C. Validating cancer drug targets. Nature 2006; 441: 451-456.
158. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG, Hogenesch JB. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 2002; 99: 4465-4470.
159. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004; 101: 6062-6067.
160. Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BF, Peters GJ. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 1995; 72: 917-921.
161. Zappa F, Ward T, Pedrinis E, Butler J, McGown A. NAD(P)H:quinone oxidoreductase 1 expression in kidney podocytes. J Histochem Cytochem 2003; 51: 297-302.
162. Hanna WT, Krauss S, Regester RF, Murphy WM. Renal disease after mitomycin C therapy. Cancer 1981; 48: 2583-2588.
163. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 2003; 3: 563-570.
164. Anders HJ, Vielhauer V. Identifying and validating novel targets with in vivo disease models:guidelines for study design. Drug Discov Today 2007; 12: 446-451.
165. Lewandoski M. Conditional control of gene expression in the mouse. Nat Rev Genet 2001; 2: 743-755.
166. Singh M, Johnson L. Using genetically engineered mouse models of cancer to aid drug development:an industry perspective. Clin Cancer Res 2006; 12: 5312-5328.
167. Berg AL, Bohlooly Y. The program for phenotyping of genetically modified animals at AstraZeneca. Exp Toxicol Pathol 2006; 57: 383-384.
168. Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res 2004; 32: 3836-45.
169. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 2003; 100: 6347-6352.
170. Cairns MJ, Saravolac EG, Sun LQ. Catalytic DNA: a novel tool for gene suppression. Curr Drug Targets 2002; 3: 269-279.
171. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347-355.
172. Honore P, Kage K, Mikusa J, Watt AT, Johnston JF, Wyatt JR, Faltynek CR, Jarvis MF, Lynch K. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 2002; 99: 11-19.
173. Dias N, Stein CA. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2002; 54: 263-269.
174. Chatterjee-Kishore M, Miller CP. Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation. Drug Discov Today 2005; 10: 1559-1565.
175. Li QX, Tan P, Ke N, Wong-Staal F. Ribozyme technology for cancer gene target identification and validation. Adv Cancer Res 2007; 96: 103-143.
176. Rossi JJ. Ribozymes, genomics and therapeutics. Chem Biol 1999;6:R33-R37.
177. Lu PY, Xie F, Woodle MC. In Vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005; 54: 117-142.
178. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, Shen Y. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258.
179. Xu H, Wilcox D, Nguyen P, Voorbach M, Suhar T, Morgan SJ, An WF, Ge L, Green J, Wu Z, Gimeno RE, Reilly R, Jacobson PB, Collins CA, Landschulz K, Surowy T. Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile. Biochem Biophys Res Commun 2006; 349: 439-448.
180. Xu H, Wilcox D, Nguyen P, Voorbach M, Smith H, Brodjian S, Suhar T, Reilly RM, Jacobson PB, Collins CA, Landschulz K, Surowy TK. Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes fatty acid composition. Front Biosci 2007; 12: 3781-3794.
181. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
182. Akai S, Hosomi H, Minami K, Tsuneyama K, Katoh M, Nakajima M, Yokoi T. Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity. J Biol Chem 2007; 282: 23996-24003.
183. Cattley RC. Peroxisome proliferators and receptor-mediated hepatic carcinogenesis. Toxicol Pathol 2004;32 Suppl 2:6-11.
184. Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 1999; 22: 1-8.
185. Kramer JA, Blomme EA, Bunch RT, Davila JC, Jackson CJ, Jones PF, Kolaja KL, Curtiss SW. Transcription profiling distinguishes dose-dependent effects in the livers of rats treated with clofibrate. Toxicol Pathol 2003; 31: 417-431.
186. Crunkhorn SE, Plant KE, Gibson GG, Kramer K, Lyon J, Lord PG, Plant NJ. Gene expression changes in rat liver following exposure to liver growth agents: role of Kupffer cells in xenobiotic-mediated liver growth. Biochem Pharmacol 2004; 67: 107-118.
187. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Bennett L, Li L, Tennant R, Stoll R, Barrett JC, Paules RS, Blanchard K, Afshari CA. Prediction of compound signature using high density gene expression profiling. Toxicol Sci 2002; 67: 232-240.
188. Grenet O, Varela MC, Staedtler F, Steiner S. The cyclosporine A-induced decrease in rat renal calbindin-D28kDa protein as a consequence of a decrease in its mRNA. Biochem Pharmacol 1998; 55: 1131-1133.
189. Varela MC, Arce A, Greiner B, Schwald M, Aicher L, Wahl D, Grenet O, Steiner S. Cyclosporine A-induced decrease in calbindin-D 28kDa in rat kidney but not in cerebral cortex and cerebellum. Biochem Pharmacol 1998; 55: 2043-2046.
190. Waring JF, Anderson MG. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr Opin Drug Discov Devel 2005; 8: 59-65.
191. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513-539.
192. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33: 1-5.
193. Watkins PB. Insight into hepatotoxicity: The troglitazone experience. Hepatology 2005; 41: 229-230.
194. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 36-38.
195. Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 1080.
196. Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999; 130: 163-164.
197. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-1156.
198. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979; 76: 170-177.
199. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329: 15-19.
200. Bousquet J, Demoly P, Hillaire-Buys D, Blayac JP, Godard P, Michel FB. [Drug allergies: a public health problem]. Bull Acad Natl Med 2000; 184: 737-750.
201. Williams DP, Park BK. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov Today 2003; 8: 1044-1050.
202. Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel 2001; 4: 55-59.
203. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 2000; 356: 1587-1591.
204. Park BK, Kitteringham NR, Powell H, Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39-60.
205. Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy-is there a connection? J Pharmacol Exp Ther 2003; 307: 1-8.
206. Liguori MJ, Waring JF. Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions. Expert Opin Drug Metab Toxicol 2006; 2: 835-846.
207. Shenton JM, Chen J, Uetrecht JP. Animal models of idiosyncratic drug reactions. Chem Biol Interact 2004; 150: 53-70.
208. Furst SM, Luedke D, Gaw HH, Reich R, Gandolfi AJ. Demonstration of a cellular immune response in halothane-exposed guinea pigs. Toxicol Appl Pharmacol 1997; 143: 245-255.
209. Shenton JM, Teranishi M, Abu-Asab MS, Yager JA, Uetrecht JP. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem Res Toxicol 2003; 16: 1078-1089.
210. Masson MJ, Uetrecht JP. Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem Res Toxicol 2004; 17: 82-94.
211. Luyendyk JP, Shores KC, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol Sci 2002; 68: 220-225.
212. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003; 307: 9-16.
213. Luyendyk JP, Maddox JF, Green CD, Ganey PE, Roth RA. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 2004; 40: 1342-1351.
214. Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 2002; 300: 460-467.
215. Luyendyk JP, Mattes WB, Burgoon LD, Zacharewski TR, Maddox JF, Cosma GN, Ganey PE, Roth RA. Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol Sci 2004; 80: 203-213.
216. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-392.
217. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 1999; 21: 407-421.
218. Bertino J, Jr., Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817.
219. Liguori MJ, Anderson LM, Bukofzer S, McKim J, Pregenzer JF, Retief J, Spear BB, Waring JF. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 2005; 41: 177-186.
220. Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, Roth RA. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2005; 316: 1080-7.
221. Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, Maddox JF, Ganey PE, Roth RA. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 2006; 319: 1191-1199.
222. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003; 192: 307-322.
223. Masubuchi Y, Nakayama S, Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002; 35: 544-551.
224. Cantoni L, Valaperta R, Ponsoda X, Castell JV, Barelli D, Rizzardini M, Mangolini A, Hauri L, Villa P. Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity. J Hepatol 2003; 38: 776-783.
225. Greaves RR, Agarwal A, Patch D, Davies SE, Sherman D, Reynolds N, Rolles K, Davidson BR, Burroughs AK. Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure. Eur J Gastroenterol Hepatol 2001; 13: 71-73.
226. Kim JW, Jeon WK, Yun JW, Park DI, Cho YK, Sung IK, Sohn CI, Kim BI, Yeom JS, Park HS, Kim EJ, Shin MS. Protective effects of bovine colostrum on non-steroidal anti-inflammatory drug induced intestinal damage in rats. Asia Pac J Clin Nutr 2005; 14: 103-107.
227. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820-827.
228. Seitz S, Boelsterli UA. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 1998; 115: 1476-1482.
229. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5: 845-856.
230. Fostel JM. Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery. Pharmacogenomics 2007; 8: 425-430.
231. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, et al. The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006; 24: 1151-1161.
232. Baken KA, Pennings JL, Jonker MJ, Schaap MM, de Vries A, Van Steeg H, Breit TM, Van Loveren H. Overlapping gene expression profiles of model compounds provide opportunities for immunotoxicity screening. Toxicol Appl Pharmacol 2007; 226: 46-59.
233. Baken KA, Vandebriel RJ, Pennings JL, Kleinjans JC, Van Loveren H. Toxicogenomics in the assessment of immunotoxicity. Methods 2007; 41: 132-141.
234. Kultima K, Nystrom AM, Scholz B, Gustafson AL, Dencker L, Stigson M. Valproic acid teratogenicity: a toxicogenomics approach. Environ Health Perspect 2004; 112: 1225-1235.